Department of Anesthesiology, University of California, San Diego School of Medicine, 200 W, Arbor Drive, San Diego, CA 92103-8770, USA.
BMC Med. 2013 Oct 31;11:233. doi: 10.1186/1741-7015-11-233.
Perhaps no greater challenge exists for public health, patient safety, and shared global health security, than fake/falsified/fraudulent, poor quality unregulated drugs, also commonly known as "counterfeit medicines", now endemic in the global drug supply chain. Counterfeit medicines are prevalent everywhere, from traditional healthcare settings to unregulated sectors, including the Internet. These dangerous medicines are expanding in both therapeutic and geographic scope, threatening patient lives, leading to antimicrobial resistance, and profiting criminal actors.
Despite clear global public health threats, surveillance for counterfeit medicines remains extremely limited, with available data pointing to an increasing global criminal trade that has yet to be addressed appropriately. Efforts by a variety of public and private sector entities, national governments, and international organizations have made inroads in combating this illicit trade, but are stymied by ineffectual governance and divergent interests. Specifically, recent efforts by the World Health Organization, the primary international public health agency, have failed to adequately incorporate the broad array of stakeholders necessary to combat the problem. This has left the task of combating counterfeit medicines to other organizations such as UN Office of Drugs and Crime and Interpol in order to fill this policy gap.
To address the current failure of the international community to mobilize against the worldwide counterfeit medicines threat, we recommend the establishment of an enhanced global health governance trilateral mechanism between WHO, UNODC, and Interpol to leverage the respective strengths and resources of these organizations. This would allow these critical organizations, already engaged in the fight against counterfeit medicines, to focus on and coordinate their respective domains of transnational crime prevention, public health, and law enforcement field operations. Specifically, by forming a global partnership that focuses on combating the transnational criminal and patient safety elements of this pre-eminent global health problem, there can be progress against counterfeit drugs and their purveyors.
对于公共卫生、患者安全和全球共享卫生安全来说,没有什么比假药、劣质不受监管药物(通常也称为“假药”)更大的挑战了,假药现在在全球药品供应链中普遍存在。假药无处不在,从传统医疗保健环境到不受监管的部门,包括互联网。这些危险药物在治疗和地理范围上都在扩大,威胁着患者的生命,导致抗菌素耐药性,并使犯罪分子受益。
尽管存在明显的全球公共卫生威胁,但对假药的监测仍然非常有限,现有数据表明,全球犯罪贸易不断扩大,但尚未得到适当解决。各种公共和私营部门实体、各国政府和国际组织都在努力打击这种非法贸易,但由于治理不力和利益分歧而受阻。具体来说,世界卫生组织(主要的国际公共卫生机构)最近的努力未能充分纳入打击这一非法贸易所需的广泛利益相关者。这使得打击假药的任务留给了其他组织,如联合国毒品和犯罪问题办公室和国际刑警组织,以填补这一政策空白。
为了解决国际社会未能动员起来应对全球假药威胁的现状,我们建议在世卫组织、联合国毒品和犯罪问题办公室和国际刑警组织之间建立一个强化的全球卫生治理三方机制,利用这些组织各自的优势和资源。这将使这些已经参与打击假药的关键组织能够专注于并协调各自在预防跨国犯罪、公共卫生和执法领域行动方面的工作。具体来说,通过形成一个专注于打击这一首要全球卫生问题的跨国犯罪和患者安全要素的全球伙伴关系,可以在打击假药及其供应商方面取得进展。